<a href="https://laohu8.com/S/XAGE">Longevity Health</a> Holdings Announces Merger with THPlasma and Ends 20/20 Biolabs Deal
Longevity Health Holdings Inc. (Nasdaq: XAGE) has announced a definitive merger agreement with True Health Inc., operating under the THPlasma brand, in an all-stock transaction aimed at combining their operations. The merger, unanimously approved by the boards of both companies, is slated to close in the fourth quarter of 2025, subject to customary closing conditions. Post-closing, the combined entity will continue trading on Nasdaq under the symbol "XAGE." As part of the agreement, THPlasma is valued at $59 million, with an additional $20 million earnout based on financial performance, and Longevity stock is valued at $3.00. Leadership roles post-merger will see Mr. Rajiv Shukla serving as Executive Chairman, while Mr. George Chi will take on the roles of Co-Chairman and CEO.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longevity Health Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-095608), on July 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。